DYAX: Dyax Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp.

DYAX 38.41

0.0%

Jan 25 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (1)	1/10/2001 5:22:08 PM
From: keokalani'nui	Read Replies (2) of 197

One explanation appears to be this, from the HQ conf: dyax claims it has the dominant phage patent position. It has 50+ licensees. It has licensed non-exclusive use in therapeutic, invitro diagnostics and research kits. It has retained exclusive rights for separations and diagnostic imaging (this program now exclusively partnered with Bracco). Also helpful may be the citations in S. Sidhu's review "Phage display in pharmaceutical biotechnology" in Curr Op on Biotechnology vol 11, 2000, which describes the various membrane proteins that can be manipulated in phage work. Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next